Novo Nordisk and Eli Lilly Slash Prices for Obesity Drugs Amid Intensifying Competition
Novo Nordisk reduces Wegovy's price to $499, while Eli Lilly cuts Zepbound's starter dose to $349, both targeting uninsured patients.
Overview
Novo Nordisk has halved the price of Wegovy to $499 for cash-paying patients as competition in the obesity drug market heats up, with Eli Lilly also slashing Zepbound's costs. Both companies aim to improve access for uninsured patients as supplies stabilize following FDA declarations lifting shortages. The changes reflect a broader trend where drug manufacturers are adjusting pricing strategies amid escalating competition and potential market saturation.
Content generated by AI—learn more or report issue.
Get both sides in 5 minutes with our daily newsletter.
Analysis
Analysis unavailable for this viewpoint.
Articles (3)
Center (0)
No articles found in the Center category
FAQ
The new price of Wegovy for cash-paying patients is $499 per month, which represents a 23% reduction from the previous price of $650.
Eli Lilly has cut the price of its starter dose of Zepbound to $349, while larger doses are available for $499. In contrast, Novo Nordisk offers all doses of Wegovy at $499.
The price reductions were prompted by improved supply conditions following FDA declarations that lifted shortages. This move reflects a broader trend of drug manufacturers adjusting pricing strategies amid escalating competition and potential market saturation.
The reduced pricing of Wegovy is available to patients without insurance or those with commercial insurance that does not cover obesity medications.
History
- This story does not have any previous versions.